IDH2 and glioma: Based on the classification of IDH mutation status, followed prognostic Meta‐analysis indicated that high expression of TP73 still showed a strong high‐risk factor in IDH‐mutant WHO grade II/III glioma (Figure 4B); while TP73 high expression as a factor impacting survival prognosis was not so strong in IDH‐wildtype subtype (Figure S6A).